Haemonetics Gains FDA Approval for Enhanced Vascular Closure System VASCADE MVP® XL
- Haemonetics receives FDA approval for the VASCADE MVP® XL, enhancing vascular closure capabilities for larger procedural sheaths.
- The VASCADE MVP XL system shows a median ambulation time of 2.4 hours, improving patient care efficiency.
- Haemonetics aims to strengthen its market presence and enhance healthcare outcomes with innovative vascular closure solutions.
Haemonetics Expands Vascular Closure Capabilities with FDA Approval
Haemonetics Corporation, a frontrunner in medical technology, secures a significant advancement in its vascular closure system with recent FDA approval that broadens the application of its VASCADE MVP® XL. This newly approved system is now compatible with larger procedural sheaths measuring 10-14F inner diameter and up to 17F outer diameter, aligning with emerging procedural techniques such as pulsed field ablation (PFA) and left atrial appendage closure (LAAC) used in the management of atrial fibrillation. The approval follows promising results from the AMBULATE EXPAND trial, which showcased an exceptional safety profile with zero major or minor complications related to access site closures, reaffirming the device’s reliability in high-demand clinical environments.
The AMBULATE EXPAND trial involved 77 patients across eight centers in the U.S. The results reveal a median ambulation time of just 2.4 hours post-procedure, highlighting the efficiency and patient-centric design of the VASCADE MVP XL system. This notable reduction in procedural time arises from the device's capability to accommodate larger sheaths without necessitating downsizing, a factor that has traditionally extended recovery burdens on patients. Haemonetics’ decision to advance its device capabilities addresses a vital market need, thereby enhancing treatment outcomes for patients while simultaneously streamlining operations for medical staff in hospitals and ambulatory surgical centers.
Ken Crowley, Vice President and General Manager of Interventional Technologies at Haemonetics, emphasizes that the clinical benefits of the VASCADE MVP XL will not only enhance patient safety but also contribute positively to healthcare economics. The approval signifies an important step in Haemonetics' strategy to fortify its presence in the U.S. market, particularly within the interventional and electrophysiology sectors. The company’s broader portfolio of VASCADE vascular closure systems is dedicated to enabling rapid hemostasis and minimizing complications, which ultimately enhances patient satisfaction and facilitates same-day discharge, aligning with the growing demand for efficient healthcare solutions.
In addition to this exciting approval, Haemonetics continues to focus on developing technologies that improve patient care through innovation. The company’s commitment to research and development ensures that it remains at the forefront of advancements in medical technology, particularly in the growing field of cardiovascular treatment. By addressing the evolving needs of healthcare providers and patients alike, Haemonetics is well-positioned to lead in the vascular closure market as it evolves.